JP2023531269A5 - - Google Patents

Info

Publication number
JP2023531269A5
JP2023531269A5 JP2022580317A JP2022580317A JP2023531269A5 JP 2023531269 A5 JP2023531269 A5 JP 2023531269A5 JP 2022580317 A JP2022580317 A JP 2022580317A JP 2022580317 A JP2022580317 A JP 2022580317A JP 2023531269 A5 JP2023531269 A5 JP 2023531269A5
Authority
JP
Japan
Prior art keywords
group
substituted
independently
alkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022580317A
Other languages
English (en)
Japanese (ja)
Other versions
JP7860003B2 (ja
JP2023531269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/103372 external-priority patent/WO2022002102A1/en
Publication of JP2023531269A publication Critical patent/JP2023531269A/ja
Publication of JP2023531269A5 publication Critical patent/JP2023531269A5/ja
Application granted granted Critical
Publication of JP7860003B2 publication Critical patent/JP7860003B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022580317A 2020-06-30 2021-06-30 キナゾリン化合物、その製造方法および用途 Active JP7860003B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020099104 2020-06-30
CNPCT/CN2020/099104 2020-06-30
CNPCT/CN2021/075828 2021-02-07
CN2021075828 2021-02-07
PCT/CN2021/103372 WO2022002102A1 (en) 2020-06-30 2021-06-30 Quinazoline compounds, preparation methods and uses thereof

Publications (3)

Publication Number Publication Date
JP2023531269A JP2023531269A (ja) 2023-07-21
JP2023531269A5 true JP2023531269A5 (cg-RX-API-DMAC7.html) 2024-06-24
JP7860003B2 JP7860003B2 (ja) 2026-05-15

Family

ID=79317503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580317A Active JP7860003B2 (ja) 2020-06-30 2021-06-30 キナゾリン化合物、その製造方法および用途

Country Status (5)

Country Link
US (1) US20230242544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175947A4 (cg-RX-API-DMAC7.html)
JP (1) JP7860003B2 (cg-RX-API-DMAC7.html)
CN (1) CN115836055A (cg-RX-API-DMAC7.html)
WO (1) WO2022002102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021215544A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US12702658B2 (en) 2020-04-24 2026-08-11 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
TWI829003B (zh) * 2020-08-12 2024-01-11 美商建南德克公司 喹唑啉化合物之合成
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN116323624B (zh) * 2020-09-30 2026-07-10 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
WO2022105859A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022109487A1 (en) 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
MX2023008463A (es) * 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
KR20230169967A (ko) * 2021-03-12 2023-12-18 브리스톨-마이어스 스큅 컴퍼니 Kras g12d 억제제
CN115260214A (zh) * 2021-04-29 2022-11-01 药雅科技(上海)有限公司 稠环类krasg12d突变蛋白抑制剂的制备及其应用
CN115160309B (zh) * 2021-04-07 2024-04-09 药雅科技(上海)有限公司 Krasg12c突变蛋白杂环类抑制剂的制备及其应用
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
CN117715915A (zh) * 2021-04-09 2024-03-15 杭州英创医药科技有限公司 作为kras g12d抑制剂的杂环化合物
WO2022221386A1 (en) * 2021-04-14 2022-10-20 Erasca, Inc. Selective kras inhibitors
US20240239788A1 (en) * 2021-04-16 2024-07-18 Merck Sharp & Dohme Llc Small molecule inhibitors of kras g12d mutant
WO2022232331A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
EP4329888A1 (en) * 2021-04-29 2024-03-06 Amgen Inc. 2-aminobenzothiazole compounds and methods of use thereof
EP4332105A4 (en) * 2021-04-30 2025-05-28 Genfleet Therapeutics (Shanghai) Inc. PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
CN115385938A (zh) * 2021-05-25 2022-11-25 江苏恒瑞医药股份有限公司 苯并嘧啶类化合物、其制备方法及其在医药上的应用
CN117500799A (zh) * 2021-06-09 2024-02-02 伊莱利利公司 作为kras g12d抑制剂的取代的稠合吖嗪
WO2022258974A1 (en) * 2021-06-10 2022-12-15 Redx Pharma Plc Quinazoline derivatives useful as ras inhibitiors
CN115466272A (zh) * 2021-06-11 2022-12-13 博瑞生物医药(苏州)股份有限公司 一种嘧啶并杂环化合物,包含其的药物组合物及其用途
WO2022262686A1 (en) * 2021-06-13 2022-12-22 Jingrui Biopharma Co., Ltd. Kras g12d inhibitors
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates
CA3221811A1 (en) * 2021-06-30 2023-01-05 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of kras g12d mutant
CA3227138A1 (en) 2021-07-23 2023-01-26 Theras, Inc. Compositions and methods for inhibition of ras
EP4378478A4 (en) 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
WO2023039240A1 (en) * 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
EP4417606A4 (en) * 2021-10-15 2025-10-22 Sunshine Lake Pharma Co Ltd NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
WO2023072188A1 (zh) * 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2023103523A1 (zh) * 2021-12-09 2023-06-15 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
JP7629580B1 (ja) * 2022-01-21 2025-02-13 ユーシノヴァ・ファーマシューティカルズ・リミテッド ベンゾピリミジン化合物及びその使用
IL314486A (en) * 2022-02-03 2024-09-01 Mirati Therapeutics Inc Quinazoline compounds inhibit PAN-KRAS
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023151621A1 (zh) * 2022-02-11 2023-08-17 泰励生物科技(上海)有限公司 具有抗kras突变肿瘤活性的化合物
CN118715215A (zh) * 2022-02-16 2024-09-27 美国安进公司 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
JP2025510656A (ja) * 2022-03-24 2025-04-15 ベイジーン スウィッツァーランド ゲーエムベーハー 複素環式化合物、その組成物、及びそれらを用いた治療方法
CN114573438A (zh) * 2022-03-31 2022-06-03 上海应用技术大学 一种单氟氯/溴代丙酮类化合物及其制备方法
CN116891488B (zh) * 2022-04-11 2025-12-12 成都海博为药业有限公司 稠环化合物、包含其的药物组合物及应用
AU2023265688A1 (en) 2022-05-06 2024-10-17 PAQ Therapeutics Inc. Kras g12d proteolysis targeting chimeras
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202400600A (zh) * 2022-06-16 2024-01-01 美商昂勝醫療科技股份有限公司 喹唑啉衍生物、其組成物及方法
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024019103A1 (ja) 2022-07-21 2024-01-25 アステラス製薬株式会社 G12d変異krasタンパクに作用する複素環化合物
CN120019052A (zh) * 2022-08-05 2025-05-16 瑟拉斯有限公司 用于抑制kras的组合物和方法
US20260035376A1 (en) * 2022-08-05 2026-02-05 Theras, Inc. Compositions and methods for inhibition of ras
JPWO2024034591A1 (cg-RX-API-DMAC7.html) 2022-08-09 2024-02-15
KR20250048078A (ko) 2022-08-11 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 Kras 억제제
AU2023322690A1 (en) * 2022-08-12 2025-03-20 Astellas Pharma Inc. Anti cancer combinations comprising chemotherapy
EP4568674A1 (en) 2022-08-12 2025-06-18 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024061333A1 (zh) * 2022-09-21 2024-03-28 甘李药业股份有限公司 一种kras突变蛋白抑制剂、及其制备方法和应用
KR20250075709A (ko) * 2022-09-30 2025-05-28 트라스베다 리미티드 항-kras 돌연변이 종양 활성을 갖는 화합물
CN117886833A (zh) * 2022-10-13 2024-04-16 广东东阳光药业股份有限公司 一种嘧啶并吡啶化合物、其药物组合物及其用途
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用
AU2023377064A1 (en) 2022-11-09 2025-05-22 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
CN116554208A (zh) * 2022-12-02 2023-08-08 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
WO2024158242A1 (ko) * 2023-01-25 2024-08-02 주식회사 엔바이오스 Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
AR133027A1 (es) 2023-06-22 2025-08-20 Astellas Pharma Inc Composición farmacéutica que comprende un compuesto de quinazolina
JP2026523985A (ja) * 2023-06-28 2026-07-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ピリミドピリジン化合物、その医薬組成物及びその使用
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024337016A1 (en) * 2023-09-08 2026-04-16 Tyligand Bioscience (Shanghai) Limited Ras inhibitor
KR20260087586A (ko) 2023-10-03 2026-06-11 피에이큐 테라퓨틱스 인코포레이티드 Kras 단백질분해 표적화 키메라
TW202523324A (zh) * 2023-10-08 2025-06-16 大陸商成都海博為藥業有限公司 一種稠環化合物及應用
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
KR20260084633A (ko) * 2023-10-10 2026-06-05 청두 하이퍼웨이 파마슈티컬스 컴퍼니 리미티드 축합 고리 화합물 및 kras 억제제로서의 응용
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025085580A1 (en) * 2023-10-17 2025-04-24 Windermere Therapeutics, Inc. Kras(g12d) inhibitors
KR20260096846A (ko) 2023-10-20 2026-06-24 머크 샤프 앤드 돔 엘엘씨 Kras 단백질의 소분자 억제제
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380928B (es) * 2013-10-10 2025-03-12 Araxes Pharma Llc Inhibidores de kras g12c.
US10011600B2 (en) * 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
KR102932353B1 (ko) * 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN110869358A (zh) * 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物,其制法与医药上的用途
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN116323624B (zh) * 2020-09-30 2026-07-10 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
US20240034733A1 (en) * 2020-11-03 2024-02-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022105859A1 (en) * 2020-11-20 2022-05-27 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors

Similar Documents

Publication Publication Date Title
JP2023540228A5 (cg-RX-API-DMAC7.html)
JP2022533939A5 (cg-RX-API-DMAC7.html)
JP2014517017A5 (ja) 化合物、その医薬組成物、及び癌治療用の阻害薬としてのその使用
JP2020521741A5 (cg-RX-API-DMAC7.html)
JP2009511490A5 (cg-RX-API-DMAC7.html)
RU2010111551A (ru) Замещенные индольные производные и способы их применения
JP2022529700A5 (cg-RX-API-DMAC7.html)
JP2024512154A5 (cg-RX-API-DMAC7.html)
RU2009127855A (ru) 4,5 циклоаннелированные производные индола для лечения или предотвращения вируса гепатита с (hcv) и родственных вирусных инфекций
JP2015057390A5 (cg-RX-API-DMAC7.html)
RU2010106878A (ru) Комбинация антимитотического агента и ингибитора аврора киназы как средство для лечения рака
JP2016509047A5 (cg-RX-API-DMAC7.html)
RU2010111550A (ru) 2,3-замещенные индольные производные для лечения вирусных инфекций
RU2011110908A (ru) Тиенопиримидины для фармацевтических композиций
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
JP2009535307A5 (cg-RX-API-DMAC7.html)
JP2022553702A5 (cg-RX-API-DMAC7.html)
JP2024532845A5 (cg-RX-API-DMAC7.html)
JP2023164918A5 (cg-RX-API-DMAC7.html)
JP2023543254A5 (cg-RX-API-DMAC7.html)
JP2010533699A5 (cg-RX-API-DMAC7.html)
JP2024543934A5 (cg-RX-API-DMAC7.html)
JP2006507355A5 (cg-RX-API-DMAC7.html)
RU2010113358A (ru) Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов
JP2023545588A5 (cg-RX-API-DMAC7.html)